← back to search

Ruth Halaban

Yale University · US
Area of research
Molecular Biology · Cell Biology
Research interest
Research interests include Melanoma and MAPK Pathways, melanin and skin pigmentation, Cutaneous Melanoma Detection and Management, and Cancer Immunotherapy and Biomarkers.
h-index
65
citations
20,076
works
277
NIH funding
primary concept
Biology
email

Recent publications

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Cancer Cell 2025cited by 34position: middledoi
Abstract 153: High-resolution profiling of the tumor microenvironment with spatial ecotypes
Cancer Research 2025cited by 0position: middledoi
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Journal for ImmunoTherapy of Cancer 2024cited by 12position: middledoi
Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5
Cell Reports 2023cited by 31position: middledoi
Retrospective cell lineage reconstruction in humans by using short tandem repeats
Cell Reports Methods 2021cited by 25position: middledoi
Retrospective cell lineage reconstruction in Humans using short tandem repeats
bioRxiv (Cold Spring Harbor Laboratory) 2017cited by 4position: middledoi
Germline MC1R status influences somatic mutation burden in melanoma
Nature Communications 2016cited by 126position: middledoi
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
Oncogene 2016cited by 58position: middledoi
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Nature Genetics 2015cited by 405position: lastdoi
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine 2014cited by 15position: middledoi
Identification of <scp>PLX</scp>4032‐resistance mechanisms and implications for novel <scp>RAF</scp> inhibitors
Pigment Cell & Melanoma Research 2013cited by 57position: middledoi
Clonal growth of human melanocytes using cell‐free extracellular matrix
Pigment Cell & Melanoma Research 2013cited by 5position: middledoi
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Nature Genetics 2012cited by 1,186position: lastdoi
Preexisting <i>MEK1</i> Exon 3 Mutations in <i>V600E/K</i> <i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Cancer Discovery 2012cited by 95position: middledoi
Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate
Proceedings of the National Academy of Sciences 2012cited by 84position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Antonella Bacchiocchi · Yale Cancer Center6 papers (2012–2025)Michael Krauthammer · University of Zurich4 papers (2012–2016)Natapol Pornputtapong · Pennsylvania State University2 papers (2015–2016)Christoph A. Klein · University Hospital Regensburg2 papers (2017–2021) · 2 papers (2017–2021)Amos Onn · University of Regensburg2 papers (2017–2021)Joseph Schlessinger · Yale University2 papers (2012–2015) · 2 papers (2017–2021)Tamir Biezuner · European Molecular Biology Laboratory2 papers (2017–2021)Perry Evans · Children's Hospital of Philadelphia2 papers (2013–2015)Liming Tao · Anhui Medical University2 papers (2017–2021) · 2 papers (2017–2021)Elaine Cheng · Yale University2 papers (2013–2015)Harriet M. Kluger · Yale Cancer Center2 papers (2015–2024)Sandra Huber · University of Regensburg2 papers (2017–2021) · 2 papers (2017–2021)Titus J. Boggon · Yale Cancer Center2 papers (2012–2013) · 2 papers (2017–2021) · 2 papers (2017–2021) · 2 papers (2017–2021)